{"id":"flecainide-injectable-solution","safety":{"commonSideEffects":[{"rate":"19-21%","effect":"Dizziness"},{"rate":"10-12%","effect":"Dyspnea"},{"rate":"7-10%","effect":"Palpitations"},{"rate":"4-6%","effect":"Chest pain"},{"rate":"7-9%","effect":"Tremor"},{"rate":"7-8%","effect":"Blurred vision"},{"rate":"9-11%","effect":"Nausea"},{"rate":"1-3%","effect":"Proarrhythmic effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Flecainide works by inhibiting fast inward sodium currents in cardiac tissue, which decreases the rate of depolarization and slows conduction through the atria and ventricles. This action suppresses ectopic activity and stabilizes the electrical properties of the myocardium, making it effective for treating various cardiac arrhythmias. The drug has minimal effects on repolarization, distinguishing it from Class IA and IB agents.","oneSentence":"Flecainide is a Class IC antiarrhythmic agent that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:53.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal supraventricular tachycardia (PSVT)"},{"name":"Paroxysmal atrial fibrillation"},{"name":"Ventricular arrhythmias"}]},"trialDetails":[{"nctId":"NCT05549752","phase":"PHASE3","title":"Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia","status":"RECRUITING","sponsor":"Hippocration General Hospital","startDate":"2023-03-24","conditions":"Atrial Fibrillation Paroxysmal, Coronary Artery Disease Without Residual Ischemia","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Flecainide Injectable Solution","genericName":"Flecainide Injectable Solution","companyName":"Hippocration General Hospital","companyId":"hippocration-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flecainide is a Class IC antiarrhythmic agent that blocks cardiac sodium channels to slow conduction velocity and suppress abnormal electrical activity in the heart. Used for Paroxysmal supraventricular tachycardia (PSVT), Paroxysmal atrial fibrillation, Ventricular arrhythmias.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}